Bristol-Myers Squibb Company PFD CONV 2
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-93.0% vs price
Base Case (Median)
-87.2% vs price
Bull Case (75th pct.)
-80.8% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $-258.18 | -164.5% | High (40%) |
| PE Comparable | $78.91 | -80.3% | Medium (25%) |
| Graham Number | $26.93 | -93.3% | Medium (40%) |
| EV/EBITDA | $71.26 | -82.2% | Medium (20%) |
| EV/FCF | $116.69 | -70.8% | Medium (20%) |
| Earnings Power Value | $31.33 | -92.2% | Medium (50%) |
Based on 6 out of 8 methods, BMYMP appears overvalued at the current price of $400.00. The base case fair value of $51.30 implies 87.2% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.